share_log
Reuters ·  May 9 06:00
Zura Bio Ltd: On Track to Initiate Phase 2 Studies Evaluating Tibulizumab (Zb-106) for Treatment of Systemic Sclerosis (Ssc) in Q4 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment